Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Premenstrual Dysphoric Disorder (PMDD): later-stage trial registry
2 of 2 indexed Premenstrual Dysphoric Disorder (PMDD) trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 2 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Premenstrual Dysphoric Disorder (PMDD): 2 US clinical trials tracked, 2 recruiting.
Premenstrual Dysphoric Disorder (PMDD) is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Johns Hopkins University, running 2 of these trials.
Enrollment posture brief
Registry condition premenstrual-dysphoric-disorder-pmdd
OPEN 2 | RECR 100% | LATE 1 | EARLY 0 | RANK #7188 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Premenstrual Dysphoric Disorder (PMDD) lists 2 open slots (100% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Premenstrual Dysphoric Disorder (PMDD) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Premenstrual Dysphoric Disorder (PMDD) is recruiting above its size-band peers.
2 of 2 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Identification and Validation of Epigenetic Biomarkers of PMDD
Johns Hopkins University
NCT06771583
Allopregnanolone and Dynamic GABA-A Receptor Plasticity in Selective Serotonin Reuptake Inhibitor Responsive Premenstrual Dysphoric Disorder
Johns Hopkins University
NCT06704594
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Premenstrual Dysphoric Disorder (PMDD) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Premenstrual Dysphoric Disorder (PMDD) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Premenstrual Dysphoric Disorder (PMDD) page
2 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Premenstrual Dysphoric Disorder (PMDD) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Johns Hopkins University sponsors the most Premenstrual Dysphoric Disorder (PMDD) trials on record, review their full trial history before evaluating a specific study. See Johns Hopkins University's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Premenstrual Dysphoric Disorder (PMDD) condition card totals 2 registered trials; most-linked intervention sertraline 50 mg daily; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.